As of May 28, 2025, Genus PLC (GNS.L) reports a Gross Margin of 36.68%.
Gross Margin indicates the portion of sales revenue remaining after covering production costs, highlighting operational efficiency.
Historical Trend of Genus PLC's Gross Margin
Over recent years, Genus PLC's Gross Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Gross Margin |
|---|---|
| 2024-06-30 | 36.68% |
| 2023-06-30 | 37.36% |
| 2022-06-30 | 36.68% |
| 2021-06-30 | 37.47% |
| 2020-06-30 | 35.98% |
This fluctuation highlights how Genus PLC manages its operational efficiency and pricing power over time.
Comparing Genus PLC's Gross Margin to Peers
To better understand Genus PLC's position, it's useful to compare its Gross Margin against industry peers. Below are selected comparisons:
| Company | Gross Margin |
|---|---|
| Genus PLC (GNS.L) | 36.68% |
| MaxCyte Inc (MXCT.L) | 8942.64% |
| Centessa Pharmaceuticals PLC (CNTA) | 7775.20% |
| Orphazyme A/S (ORPHA.CO) | 7775.20% |
| Bicycle Therapeutics PLC (BCYC) | 7775.20% |
| Compass Pathways PLC (CMPS) | 7775.20% |
Compared to its competitors, Genus PLC's Gross Margin is among the lowest compared to peers, suggesting potential challenges in production costs or pricing strategy.